Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
In the news
Recent Posts
Proactive Investors | Interview with Amplia CEO Chris Burns on clinical trial progress
Fifth partial response confirmed in ACCENT trial
Amplia receives R&D Tax Rebate
Key chemical form patents in Europe and Japan
Fourth partial response confirmed in ACCENT trial
ASX Briefs podcast | Interview with Dr Chris Burns
Categories
Archive
Company News
Investor Newsletters
Videos
30 Sep 2021
Amplia Therapeutics says ‘priming’ a tumour could improve outcomes for patients with pancreatic cancer
Read More
30 Sep 2021
Breakthrough research lowers pancreatic cancer’s resistance to chemo
Read More
30 Sep 2021
New FAK research published in Science Advances
Read More
29 Sep 2021
VIDEO | Proactive Lifesciences Webinar
Read More
27 Sep 2021
Proactive Lifesciences Webinar
Read More
22 Sep 2021
Bioshares | Amplia Therapeutics to Start Two Phase II Studies in 2022
Read More
20 Sep 2021
Proactive | Interview with Dr John Lambert
Read More
26 Jul 2021
Amplia Therapeutics phase 1 results support development of AMP945 in cancer and fibrosis
Read More
26 Jul 2021
Amplia Therapeutics develops new approach to treat cancer and fibrosis
Read More
21 Jul 2021
Amplia Therapeutics returns successful phase one trial results
Read More
19 Jul 2021
Garvan's June Seminar: The Power of Personalised Medicine
Read More
30 Jun 2021
Amplia Therapeutics partners with Garvan Institute to develop pancreatic cancer drug
Read More
28 Jun 2021
Amplia Therapeutics and Sydney’s Garvan Institute enter collaboration agreement for pancreatic cancer treatment
Read More
02 Jun 2021
Positive data sends Amplia Therapeutics nearly 50 per cent up
Read More
18 Mar 2021
Amplia Therapeutics signs agreement with Garvan Institute
Read More
17 Mar 2021
Amplia Therapeutics completes single-dose study of AMP945
Read More
14 Oct 2020
Joint Cancer Therapeutics CRC/AMPLIA Therapeutics Press Release
Read More
09 Oct 2020
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
Read More
09 Oct 2020
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
Read More
1
2
3
4
5